Despite challenges such as biomarker validation, drug delivery, and clinical trial design, the TOR1 AIP1-p53 axis offers new therapeutic strategies for PRAD patients, with the potential to significantly improve prognosis. Here, TP53 is linked to prostate adenocarcinoma.